A pharmacoeconomic analysis of Coumadin versus generic warfarin

Formulary

Volumn 33, Issue 6, 1998, Pages 573-587

  Basskin, Lorne ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; WARFARIN;

ANTICOAGULATION; COST EFFECTIVENESS ANALYSIS; DRUG BIOAVAILABILITY; DRUG COST; HUMAN; REVIEW;

EID: 0032458821     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Package insert. Warfarin sodium tablets, USP. Revised January 1997.
2. Haines ST. Reflections on generic warfarin. Am J Health-Syst Pharm 1998;55:729-33.
3. Correspondence from PDA to DuPont Merck. August 26, 1997.
4. Federal Register. August 14, 1997 (Volume 62, Number 157) (pages 43535-43538). At http://www.access.gpo.gov.
5. Basskin L. How to use decision analysis to solve pharmacoeconomic problems. Formulary 1997;32:619-28.
6. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis. N Engl J Med 1982;307:1676-81.
7. Menzin J, Colditz GA, Regan MM, et al. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 1995;155:757-64.
8. Mark DB, Talley DJ, Topol EJ. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high risk coronary angioplasty. Circulation 1996;94:629-35.
9. The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996;156:409-16.
10. Goodman LS, Gilman A, eds. The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw Hill, 1996;70-6.
11. Sawyer WT, Poe TE, Canaday BR, et al. Multicenter evaluation of six methods for predicting warfarin maintenancedose requirements from initial response. Clin Pharm 1985;4:440-6.
12. Fredriks DA, Coleman RW. Nomogram for dosing warfarin at steady state. Clin Pharm 1991;10:923-7.
13. F-D-C Reports - "The Pink Sheet." 1997;March 31:6-7.
14. Anon. Massachusetts rejects DuPont Merck petition to block Barr's generic Coumadin (news release). Barr Laboratories, Pomona, NY. November 19, 1997.
15. Anon. FDA position on product selection for "narrow therapeutic index" drugs. Am J Health-Syst Pharm 1997;54:1630-2.
16. Food and Drug Administration Center for Drug Evaluation and Research Approved Drug Products with Therapeutic Equivalence Evaluations: Preface. At http://www.accessdata.fda.gov/ob.
17. Neutel JM, Smith DHG. A randomized crossover study to compare the efficacy and tolerability of Barr warfarin sodium to the currently available Coumadin. Cardiovasc Rev Reports 1998;19:321-9.